This inventor holds 5 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Dana-Farber-Cancer Institute Inc., The General Hospital Corporation. Active years: 2021-2026.
Company Filing History:
5 out of 1,264 
1 out of 3,068 
Years Active: 2021-2026
Title: Innovations of Fleur M Ferguson
Introduction
Fleur M Ferguson is a prominent inventor based in Cambridge, MA (US). She has made significant contributions to the field of biomedical research, particularly in the development of therapeutic compounds targeting neurodegenerative diseases and cancer.
Latest Patents
Fleur M Ferguson holds 5 patents. Her latest patents include "Compounds for tau protein degradation," which describes bifunctional compounds that bind tau protein and promote its degradation through targeted ubiquitination. This innovation is particularly relevant for treating tauopathies, a group of neurodegenerative diseases characterized by tau protein aggregation. Another notable patent is "ERK5 degraders as therapeutics in cancer and inflammatory diseases," which discloses bispecific compounds that target ERK5 for degradation, offering potential treatments for cancer and inflammatory conditions.
Career Highlights
Throughout her career, Fleur has worked with esteemed organizations such as Dana-Farber Cancer Institute and The General Hospital Corporation. Her work has been instrumental in advancing therapeutic strategies for complex diseases.
Collaborations
Fleur has collaborated with notable colleagues, including Nathanael Schiander Gray and Tinghu Zhang, contributing to a rich exchange of ideas and innovations in her field.
Conclusion
Fleur M Ferguson's innovative work in developing therapeutic compounds showcases her commitment to addressing critical health challenges. Her contributions continue to impact the fields of neurodegenerative disease and cancer treatment significantly.